Zelira Therapeutics Limited (ASX:ZLD)

Market Cap	5.35M
Revenue (ttm)	40.88K
Net Income (ttm)	-4.84M
Shares Out	11.90M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,685
Average Volume	5,555
Open	0.4800
Previous Close	0.4500
Day's Range	0.4800 - 0.5000
52-Week Range	0.2730 - 1.0600
Beta	0.42
RSI	64.69
Earnings Date	May 27, 2025

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products un...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ZLD

Financial Performance

In 2024, Zelira Therapeutics's revenue was 94,952, a decrease of -68.47% compared to the previous year's 301,121. Losses were -36.57 million, 556.2% more than in 2023.